Morphic Holding (Morphic Holding) Cash-to-Debt : 200.78 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Morphic Holding's cash to debt ratio for the quarter that ended in Mar. 2024 was 200.78.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Morphic Holding could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Morphic Holding's Cash-to-Debt or its related term are showing as below:

MORF' s Cash-to-Debt Range Over the Past 10 Years
Min: 32.94 Med: 300.49 Max: No Debt
Current: 300.49

During the past 7 years, Morphic Holding's highest Cash to Debt Ratio was No Debt. The lowest was 32.94. And the median was 300.49.

MORF's Cash-to-Debt is ranked better than
84.6% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs MORF: 300.49

Morphic Holding Cash-to-Debt Historical Data

The historical data trend for Morphic Holding's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Morphic Holding Cash-to-Debt Chart

Morphic Holding Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

80.84

90.74

300.49

Morphic Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															121.13	235.16	265.59	300.49	200.78

Competitive Comparison of Morphic Holding's Cash-to-Debt

For the Biotechnology subindustry, Morphic Holding's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Morphic Holding's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Morphic Holding's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Morphic Holding's Cash-to-Debt falls into.

Morphic Holding Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Morphic Holding's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	704.349	/	(1.628	+	0.716)
	=	300.49

Morphic Holding's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	658.766	/	(1.807	+	1.474)
	=	200.78

Morphic Holding (NAS:MORF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Morphic Holding Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Morphic Holding (Morphic Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

31Y:Germany 31Y:Germany

Address

35 Gatehouse Drive, A2, Waltham, MA, USA, 02451

Website

http://www.morphictx.com

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Executives

William Devaul	officer: General Counsel and Secretary	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers	officer: Chief Scientific Officer	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin	officer: CFO and COO	ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni	director, officer: President and CEO	C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr	officer: VP Finance and Ops, Secretary	CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery	director	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer	director, 10 percent owner	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde	officer: Chief Medical Officer	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda	director	281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	director	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal	director	C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia	director	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199